Pages that link to "Q34207787"
Jump to navigation
Jump to search
The following pages link to 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. (Q34207787):
Displayed 30 items.
- Striving for optimal bronchodilation: focus on olodaterol (Q26752887) (← links)
- Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol (Q26775244) (← links)
- Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD (Q26778685) (← links)
- Positioning new pharmacotherapies for COPD (Q26798659) (← links)
- Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline (Q27348844) (← links)
- Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies (Q33783760) (← links)
- Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies (Q33890178) (← links)
- Advances in device and formulation technologies for pulmonary drug delivery (Q33962567) (← links)
- The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies (Q34123296) (← links)
- Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. (Q35766346) (← links)
- The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. (Q35865433) (← links)
- Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma (Q35875281) (← links)
- Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. (Q35965128) (← links)
- Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease (Q35994264) (← links)
- Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease (Q36158846) (← links)
- One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis (Q36652462) (← links)
- Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function (Q36729122) (← links)
- Emerging drugs for chronic obstructive pulmonary disease. (Q37984088) (← links)
- The COPD Pipeline XVII. (Q38021815) (← links)
- Future of chronic obstructive pulmonary disease management (Q38025725) (← links)
- Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review (Q38148145) (← links)
- Olodaterol: first global approval (Q38155451) (← links)
- Olodaterol: a review of its use in chronic obstructive pulmonary disease (Q38379269) (← links)
- Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. (Q38570714) (← links)
- Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease (Q38639661) (← links)
- The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis (Q39037235) (← links)
- Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. (Q47801444) (← links)
- Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review (Q58997823) (← links)
- What Does the TOVITO Programme Tell Us about How We Can Manage COPD? (Q59131559) (← links)
- Bronchodilatateurs dans la BPCO : quoi de neuf ? (Q62007504) (← links)